Dapagliflozin attenuates metabolic dysfunction-associated steatotic liver disease by inhibiting lipid accumulation, inflammation and liver fibrosis.

BMC Pharmacol Toxicol · 2025 · PMC11905655 · PMID 40075451

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In contrast, although a downward trend in hepatic TG levels was observed after DaPa administration, the change did not reach statistical significance (Fig. 3 B).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.